

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR

OMB APP	PROVAL
OMB Number:	3235-0076
Expires:	May 31, 2005
Estimated averag	e burden hours
per response	16.00
SEC USE	

DATE RECEIVED

Serial

Prefix

UNIFORM LIMITED OFFERING EXEMPTION	
Name of Offering (check if this is an amendment and name has changed, and indicate change.) EraGen Biosciences, Inc. Shares of Series A Preferred Stock and Warrants	
· · · · · · · · · · · · · · · · · · ·	OF
Filing Under (Check box(es) that apply): Rule 504 Rule 505 Rule 506 Section 4(6) U	LOE
Type of Filing: New Filing	
A. BASIC IDENTIFICATION DATA	
Enter the information requested about the issuer	
Name of Issuer (check if this is an amendment and name has changed, and indicate change.)	05068867
EraGen Biosciences, Inc.	100007
	umber (Including Area Code)
918 Deming Way, Madison, WI 53717 (608) 662-90	00
	umber (Including Area Code)
(if different from Executive Offices) Same Same	
Brief Description of Business	
Designs, develops and commercializes products and technologies that advance molecular diagnostics and accele	erate the drug discovery process.
Type of Business Organization	emoniful.
	specify):
usiness trust innited partnersing, to be formed	
Actual or Estimated Date of Incorporation or Organization: Month Year_	
03 1999 🖾 Actual	Estimated
	PROCESSED
Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State:	
CN for Canada; FN for other foreign jurisdictions)	E
	OCT 1 9 2005 \angle
GENERAL INSTRUCTIONS	
	THOMSON

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

> Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

	See a second and a	A. BASIC IDE	NTIFICATION DAT	A prayout the	The state of the s
• Each be	omoter of the issu	er, if the issuer has been	organized within the past dispose, or direct the vote		of, 10% or more of a class of equity
• Each exc	ecutive officer an	d director of corporate iss ng partner of partnership		eral and manag	ing partners of partnership issuers; and
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	Executive Officer	☑ Director	☐ General and/or Managing Partner
Full Name (Last name first, Hrusovsky, Irene	if individual)				
Business or Residence Addre 918 Deming Way, Madison		Street, City, State, Zip C	ode)		
Check Box(es) that Apply:	Promoter	Beneficial Owner	☑ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, Prudent, James	if individual)	-	-		
Business or Residence Addre 918 Deming Way, Madison		Street, City, State, Zip C	Code)		
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner		☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, Pauls Fleming, Linda	if individual)				
Business or Residence Addre 918 Deming Way, Madison		Street, City, State, Zip C	Code)		
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	General and/or Managing Partner
Full Name (Last name first, Goebel, Markus	if individual)				
Business or Residence Addre 400 Technology Square, Ca			Code)		
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, O'Bryan, David	if individual)				
Business or Residence Addre 110 Stonepine Drive, Kenn	•		Code)		
Check Box(es) that Apply:	Promoter	Beneficial Owner	☐ Executive Officer	□ Director	General and/or Managing Partner
Full Name (Last name first, Rozzell, J. David					
Business or Residence Addre 129 N. Hill Avenue, Suite 1			Code)		
Check Box(es) that Apply:	Promoter	Beneficial Owner	☐ Executive Officer	☐ Director	General and/or Managing Partner
Full Name (Last name first, Novartis Forschungsstiftun					
Business or Residence Addre c/o Novartis BioVenture Fu					

Check Box(es) that Apply:	Promoter	⊠ Beneficial Owner	☐ Executive Officer	☐ Director	General and/or Managing Partner
Full Name (Last name first, Total First Analysis Corpor					
Business or Residence Addre One South Wacker Drive,		-	Code)		
	(Use blank shee	t, or copy and use addition	nal copies of this sheet, as	s necessary.)	

n Need all		Tarahan sanggaran Establish	24178 (618193) 15-741 4 3 4 7 3 7 3 5 5 7 5 7 5 7 5 7 5 7 5 7 5 7 5	В. І	NFORMA	TION AB	OUT OFF	ERING				
1. Has	the issuer s	old, or does	the issuer in	ntend to sell	, to non-acc	redited inve	stors in this	offering?			Yes	No
Ans	wer also in .	Appendix, C	Column 2, if	filing unde	r ULOE.							
2. Wha	at is the min	imum inves	tment that w	ill be accep	ted from any	individual?	·	••••			\$ <u>100,0</u>)00
3. Doe	es the offerin	ig permit joi	nt ownershi	p of a single	unit?						Yes	No
indi with a bi brol	er the inform rectly, any n sales of sec roker or deale ker or deale ker or deale	commission curities in tha ler register er. If more	or similar ne offering. red with the than five (remuneration If a person SEC and/o(5) persons	on for solici to be listed or with a sta to be listed	tation of put is an associate or states are associa	archasers in ated person s, list the nated persons	connection or agent of ame of the				
Full Nan Bishop,	ne (Last nan Ralph	ne first, if ir	ndividual)									
	or Resident celsior Driv				y, State, Zip	Code)					·	
Name of N/A	Associated	Broker or D	Dealer									
States in	Which Pers	on Listed H	as Solicited	or Intends t	o Solicit Pur	chasers						
(Check [AL] [IL] [MT] [RI]	"All States" [AK] [IN] [NE] [SC]	or check in [AZ] [IA] [NV] [SD]	ndividual Sta [AR] [KS] [NH] [TN]	(CA) [CA] [KY] [NJ] [TX]	[CO] [LA] [NM] [UT]	[CT] [ME] [NY] [VT]	[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[FL] [MI] [OH] [WV]	[GA] [MN] [OK] [WI] >	 [HI] [MS] [OR] [WY]	All States [ID] [MO] [PA] [PR]
Full Nan Ramsey	ne (Last nan	ne first, if in	ndividual)									
Business	or Residence				y, State, Zip	Code)						
	Associated											
	Which Pers	on Listed H	as Solicited	or Intends t	o Solicit Pu	rchasers	<u>.</u>				., "	
(Check	"All States	" or check is	ndividual Sta	ates)								All States
[AL] [IL]► [MT] [RI]	[AK] [IN] [NE] [SC]	[AZ] [IA] [NV] [SD]	[AR] [KS] [NH] [TN]					[DC] [MA] [ND] [WA]		[GA] [MN] [OK] [WI]	[HI] [MS] [OR] [WY]	[ID] [MO] [PA] [PR]
Full Nar	ne (Last nan David	ne first, if is	ndividual)									
	or Resident					Code)						
Name of N/A	f Associated	Broker or I	Dealer							, .		
States in	Which Pers	son Listed H	las Solicited	or Intends	o Solicit Pu	rchasers						
(Check	"All States	" or check is	ndividual Sta	ates)								All States
[AL] [IL]► [MT] [RI]	[AK] [IN] [NE] [SC]	[AZ] [IA] [NV] [SD]	[AR] [KS] [NH] [TN]	[CA] [KY] [NJ] [TX]	[CO] [LA] [NM] [UT]	[CT] [ME] [NY] [VT]	[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[FL] [MI] [OH] [WV]	[GA] [MN] [OK] [WI]	[HI] [MS] [OR] [WY]	[ID] [MO] [PA] [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND	USE OF PROCEED)S
 Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box ☐ and indicate in the columns below the amounts of the securities offered for exchange and already exchanged. 	A	A
Type of Security	Aggregate Offering Price	Amount Already Sold
Debt	\$0	\$0
Equity	\$0	\$0
☐ Common ☒ Preferred*		
Convertible Securities (including warrants)	\$9,072,630	\$9,072,630
Partnership Interests	<u>\$0</u>	<u>\$0</u>
Other (Specify)	<u>\$0</u>	\$0
Total	\$9,072,630	\$9,072,630
*With warrants to purchase preferred shares. Answer also in Appendix, Column 3, if filing under ULOE.		,
2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		
	Number Investors	Aggregate Dollar Amount of Purchases
Accredited Investors	19	\$9,072,630
Non-accredited Investors	0	\$0
Total (for filings under Rule 504 only)	N/A	\$N/A
Answer also in Appendix, Column 4, if filing under ULOE.		
3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C-Question 1.		
Type of Offering	Type of Security	Dollar Amount Sold
Rule 505	N/A	\$N/A
Regulation A	N/A	\$N/A
Rule 504	N/A	\$N/A
Total	N/A	\$N/A
4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
Transfer Agent's Fees		\$
Printing and Engraving Costs		\$
Legal Fees	🖂	\$50,000
Accounting Fees		\$
Engineering Fees		\$

Sales Commissions (specify finders' fees separately).....

Other Expenses (identify) Finders' Fees

SEC 1972 (2/99) 5 of 6

 \boxtimes

\$226,000

\$276,000

	b. Enter the difference between the aggre Question 1 and total expenses furnishe difference is the "adjusted gross proce	egate offering price given in response to Part d in response to Part C - Question 4.a. This eds to the issuer."	C -		\$8,796,630
5.	be used for each of the purposes shown. If furnish an estimate and check the box to the	tross proceeds to the issuer used or proposed the amount for any purpose is not known, the left of the estimate. The total of the payments to the issuer set forth in response to Part C	nts		90,720,030
				Payments to Officers, Directors, &	December To
				Affiliates	Payments To Others
	Salaries and fees			\$0	
	Purchase of real estate			\$0	
	Purchase, rental or leasing and installation o	f machinery and equipment		<u>\$0</u>	
	Construction or leasing of plant buildings an	d facilities		\$0	\$0
	Acquisition of other businesses (including the Offering that may be used in exchange for the Company of the Com	ne assets or securities of another	_	60	□ .co
			_	\$0	_ <u>\$0</u>
				\$0	_ <u>\$0</u>
	Other (specify)		٠٠٠٠٠٠ ا	\$0	
				\$0	_ \$0
	Column Totals			\$0	№ \$8,796,630
	Total Payments Listed (column totals added))		⊠ \$ <u>8,796,</u>	530
	e de la companya de l	D. FEDERAL SIGNATURE	A CONTRACTOR OF THE		
nstitu	ner has duly caused this notice to be signed by tes an undertaking by the issuer to furnish to ssuer to any non-accredited investor pursuant	the U.S. Securities and Exchange Commission to paragraph (b)(2) of Rule 502.	this notice is n, upon wri	s filed under Rule 5 tten request of its st	05, the following signature aff, the information furnish
	Print or Type)	Signature		Dat	e
oCon	Riosaionaes Inc	Ira Aruso	75 hs	//	0/6/05
	Biosciences, Inc. f Signer (Print or Type)	Title of Signer (Print or Type)	-/-		, , , ,
me of	= · · · · · ·				
	rusovsky	President and Chief Executive Officer			